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Abstract
Electroconvulsive therapy (ECT) is the treatment of choice for severe and treatment-resistant
depression; disorder severity and unfavorable treatment outcomes are shown to be influenced
by an increased genetic burden for major depression (MD). Here, we tested whether ECT assign-
ment and response/nonresponse are associated with an increased genetic burden for major
depression (MD) using polygenic risk score (PRS), which summarize the contribution of disease-
related common risk variants. Fifty-one psychiatric inpatients suffering from a major depressive
episode underwent ECT. MD-PRS were calculated for these inpatients and a separate
population-based sample (n = 3,547 healthy; n = 426 self-reported depression) based on sum-
mary statistics from the Psychiatric Genomics Consortium MDD-working group (Cases:
n = 59,851; Controls: n = 113,154). MD-PRS explained a significant proportion of disease status
between ECT patients and healthy controls (p = .022, R2 = 1.173%); patients showed higher
MD-PRS. MD-PRS in population-based depression self-reporters were intermediate between
ECT patients and controls (n.s.). Significant associations between MD-PRS and ECT response
(50% reduction in Hamilton depression rating scale scores) were not observed. Our findings indi-
cate that ECT cohorts show an increased genetic burden for MD and are consistent with the
hypothesis that treatment-resistant MD patients represent a subgroup with an increased genetic
risk for MD. Larger samples are needed to better substantiate these findings.
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1 | INTRODUCTION
Effective treatments for depression remain elusive because of poor
understanding of the underlying etiology of this highly prevalent dis-
order. Electroconvulsive therapy (ECT) is the treatment of choice for
severe and treatment-resistant forms of depressive episodes (Fink &
Taylor, 2007) and thus, patients assigned to ECT represent a specific
subgroup selected for these factors. There is increasing evidence that
severity of psychiatric disorder is associated with a higher genetic bur-
den for the disorders, for example, (Amare et al., 2018; Frank et al.,
2015). Recently, this has also been demonstrated in the largest
genome-wide association study (GWAS) for depression to date (Wray
et al., 2018) which showed that major depression is a highly polygenic
disorder, that is, a result of the contribution of many genetic variants.
Polygenic risk score (PRS) profiling is an approach that uses the risk
variants and corresponding effect sizes identified in large GWAS such
as the above study as a “discovery sample” to generate risk scores in
an independent “target sample,” reflecting the disease risk burden of
each individual (Wray et al., 2014). Presently, the clinical utility of PRS
remains limited at the level of the individual as they only explain a
small share of variance in case–control status or symptom severity.
However, they can be used as a research tool to dissect disease aetiol-
ogy by investigating the association of genetic risk burden for a disor-
der with related subphenotypes. In Wray et al. 2018, higher PRS were
associated with measures of increased severity such as early age at
onset, symptom counts, and recurrent episodes (Appendix A).
In the present study, we hypothesized that as ECT patients repre-
sent a severe and treatment-resistant share of all MD patients, they
should show an increased genetic burden for MD. We aimed to assess
the feasibility of this approach to detect increased genetic risk of
depression in a group of inpatients (n = 52) assigned to ECT as com-
pared to population-based controls. We generated PRS using results
from the MD-GWAS by Wray et al. (2018) (PGC-MD2, Cases:
n = 59,851; Controls: n = 113,154), testing whether these PRS were
associated with MD ECT case–control status. In addition, we explored
MD-PRS in population based subjects with self-reported MD, and
MD-PRS associations with clinical parameters in the ECT group.
2 | MATERIALS AND METHODS
This study was approved by the ethics committee (II) at the Medical
Faculty Mannheim, University of Heidelberg. All patients provided
written consent. All procedures were performed in accordance with
the Declaration of Helsinki.
2.1 | ECT patients
Patients were recruited between 2014 and 2016 at the Department
of Psychiatry and Psychotherapy of the Central Institute of Mental
Health, Mannheim. Inclusion criteria were a present major depressive
episode within the context of a diagnosis of either major depressive
disorder or bipolar disorder according to DSM-IV, age above 18 years
and the clinical decision for an ECT treatment. Exclusion criteria were
any substance-related disorders, except tobacco and alcohol use. All
participants were of Caucasian descent.
The criteria for assigning patients with a depressive episode to
ECT were either treatment-resistant depression defined as failure of
two adequate dose-duration antidepressants or psychotherapy from
different classes in the current episode (Conway, George, & Sackeim,
2017) or positive experience to ECT from a previous episode, or
severe depression with (a) psychotic symptoms, (b) severe suicidality,
or (c) the refusal of food or fluid intake.
A total of 52 inpatients consented to participate in the present
study. In 36 of the 52 included patients (69.2%) the indication for ECT
was a current treatment-resistant depressive episode. Six patients
(11.5%) with a current depressive episode were assigned to ECT
because of positive experience to ECT during a previous depressive
episode, whereas five (9.6%) other patients received ECT because of
depression with severe psychotic symptoms. In three patients (5.8%),
the severe suicidality that was accompanied by the depressive epi-
sode was the main indication for ECT and in two patients (3.9%) the
indication was refusal of food and fluid intake. In three cases, a legal
guardian gave the formal consent to the study for the patient. All
other patients gave their consent on their own.
A comorbid personality disorder (PD) was indicated when already
diagnosed prior to the recent depressive episode. Generally, that diag-
nosis was either given after a Structured Clinical Interview for DSM-
IV Axis II Disorders (SCID-II) interview, but in some patients based on
a clinical judgment. Out of the fifteen patients with comorbid PDs,
there were seven patients with Borderline PD (46.7%), three patients
with a dependent PD (20.0%), two patients each with a histrionic
(13.3%) and avoidant PD (13.3%), respectively and one patient with
an obsessive–compulsive PD (6.7%).
Of 52 patients, 7 discontinued the treatment prematurely after
one of the initial ECT sessions: four patients discontinued ECT after
the first (n = 2), second (n = 1), or third (n = 1) session because of sub-
jective intolerable side effects; one patient left the hospital against
the medical advice after the fourth ECT session; in one patient ECT
was stopped after suffering from a serotonergic syndrome because of
ECT and concomitant medication; one patient dropped out due severe
hyponatremia during the course of treatment and subsequent transfer
to a hospital for internal medicine. Furthermore, we excluded one
patient with diagnosis of schizophrenia from statistical analyses.
2.2 | Controls
Data from Heinz Nixdorf Recall (HNR) study, a population-based
study of individuals with homogeneous German ethnicity, comprised
the control sample (n = 4,814, M:2395; F:2419). The HNR controls
had been assessed for depression status using a computer-assisted
personal interview with the question: “Do you have or have you ever
had depression? (Y/N)”. A total of n = 3,547 answered “no” and
n = 426 answered “yes”, whereas answers for n = 841 were unknown.
2.3 | Assessments
ECT patients were assessed for demographics, including: Age, sex
(male/female) and body mass index.
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Baseline clinical factors were also assessed: age at first disease
onset, length of current episode (months), multiple drug therapy resis-
tance (yes/no), presence of PD (yes/no), positive family history in first
degree relatives for affective disorders (yes/no), type of depression
(unipolar or bipolar depression), alcohol dependence or abuse
(yes/no), and nicotine dependence (yes/no).
The 21-item version of the Hamilton depression rating scale
(HDRS) was administered pre- and post-ECT treatment.
2.4 | ECT
Right unilateral brief pulse ECT was performed with a Thymatron IV
device (Somatics, LLC. Lake Bluff, IL). S-ketamine (~1.0 mg/kg) or thio-
pental (~5 mg/kg) were used as anesthetic agents and succinylcholine
(~1.0 mg/kg) for muscle relaxation. Seizure threshold was titrated at
the initial session and stimulation dose at subsequent treatments was
given at above 2.5 times the seizure threshold (Bumb et al., 2015;
Hoyer et al., 2017). Charge was subsequently adjusted if seizures
were considered as potentially insufficient during the ECT course
(e.g., motor response time <15 s or electroencephalogram (EEG) sei-
zure activity <25 s; Kranaster, Hoyer, Janke, & Sartorius, 2013).
The psychiatrist, who was responsible for the whole in-patient
treatment of the respective patient, made the clinical decision of
when to terminate the ECT course. ECT was continued until the sub-
ject showed either a remission or a stable response or did not show a
significant response after at least 12 ECT sessions. In the case of no
further and relevant clinical improvement for 2 weeks (4–6 ECT ses-
sions), ECT was terminated.
No specifications on the concomitant psychotropic medication
were made.
2.5 | Blood sampling, control data, genotyping and
quality control
A venous blood sample was collected from participants for genome-
wide genotyping. Genotyping was performed using the Global Screen-
ing Array (Illumina, Inc., San Diego, CA). The HNR sample had also
been genotyped using the Global Screening Array. The merged data
set contained n = 642,553 overlapping SNPs. The data were subjected
to a stringent quality control (QC) procedure, which included following
parameters for retainment in data set: SNP missing rates <0.05 (prior
to filtering individuals), individual missingness <0.02, autosomal het-
erozygosity deviation |Fhet| < 0.2, SNP missing rate < 0.02 (after filter-
ing individuals), minor allele frequency > 0.01, Hardy–Weinberg
equilibrium (Case: p > 1e−10, Control: p > 1e−6, Overall: p > 1e−6) and
difference in missing rate between cases and controls <0.02. Ten prin-
cipal components (PCs) were computed using principal component
analysis (PCA) on a filtered subset of frequent (MAF > 0.05) autoso-
mal SNPs in approximate linkage equilibrium (pairwise R2 < 0.1 within
a window of 250 SNPs) to find informative ancestry information and
detect and remove genetic outliers (defined as those exceeding six
standard deviations). A relatedness cutoff of Pi Hat = 0.125 was used
to exclude related individuals. Filtering was performed using PLINK
1.90 (Chang et al., 2015). After QC, the data set comprised 44 ECT
cases and 4,290 individuals from the HNR sample, with 485,607
variants remaining. Of the HNR individuals passing QC, n = 376 had
self-reported depression (HNR-DEP) and n = 3,172 were healthy con-
trols. Those with unknown depression status (n = 742) were removed
from the analysis.
2.6 | Data analysis
Statistical analyses were performed using IBM SPSS Statistics for
Windows version 24. Descriptive statistics were calculated for all
participants.
Given the sample size and uneven proportion of responders/non-
responders, we calculated nonparametric Spearman's rank correlations
to examine factors related to response. Response was examined cate-
gorically (yes/no), defined as a 50% reduction in HDRS scores, and
also a continuous variable (ΔHDRS score, the pre-post difference
between HDRS). Correlations with remission, defined as post-
treatment HDRS score > 10, were also examined.
2.7 | Polygenic risk score calculation
PRS were calculated using genome-wide association data from the
Psychiatric Genomics Consortium (PGC-MD2, Cases: n = 59,851;
Controls: n = 113,154)(Wray et al., 2018) using PRsice v 1.25
(Euesden, Lewis, & O'Reilly, 2015). Clumping was carried out to
retain only one representative variant per region of linkage disequilib-
rium (LD) using thresholds of p1 1, p2 1 an LD threshold of r2 ≥ 0.1
and a distance threshold of 500 kb. The multi histocompatibility com-
plex of chromosome 6 was excluded. Scores were calculated for a
range of p-value thresholds (5 × 10−8, 1 × 10−6, 1 × 10−4, 0.001,
0.01, 0.05, 0.1, 0.2, 0.5, 1.0). PRS were standardized to the mean and
standard deviation of controls, that is, . (PRS − meancontrols)/standard
deviationcontrols (Lewis & Vassos, 2017).
A binomial logistic regression analysis was carried out to deter-
mine the contribution of MD-PRS to disease status. Case–control sta-
tus was specified as the dependent variable. Proportion of variance
explained by PRS was tested by comparing Nagelkerke's R2 in an ini-
tial model including PCs informative of case–control status to a full
model which additionally included PRS. Data from HNR-DEP were
not included in the case–control analysis.
In a next step, we included HNR-DEP individuals passing QC
(n = 376) and calculated PRS. Using the above method, binomial
regression analyses were used to compare both ECT vs. HNR-DEP
and HNR-DEP vs. controls.
Using partial correlations (accounting for PCs informative of
case–control status), we tested whether MD-PRS were correlated
with ECT response and demographic/clinical factors in the ECT
sample.
3 | RESULTS
3.1 | Descriptive statistics
Descriptive statistics are shown on Table 1.
The correlation analysis revealed that categorical response (50%
reduction in HDRS) was statistically significantly correlated with being
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male (rho = 0.332, p = .045, df = 35), having a positive family history
for affective disorders (rho = 0.358, p = .029, df = 35), and negatively
correlated with diagnosis of PD (rho = −0.335, p = .043, df = 35).
Tobacco use was negatively correlated with response (rho = −0.290,
p = .082, df = 35) at the trend level. No other variables showed statis-
tically significant correlation with response.
Examining response as a continuous variable (ΔHDRS score)
yielded similar findings with respect to male sex (rho = 0.373,
p = .021, df = 36) and PD (rho = −0.335, p = .043, df = 35). Addition-
ally, ΔHDRS score was associated with increased age (rho = 0.363,
p = .001, df = 36), negatively associated with length of current epi-
sode (rho = −0.348, p = .035, df = 35 and positively correlated with
increased age at first disease onset (rho = 0.370, p = .022, df = 36).
No other variables showed statistically significant correlation with
ΔHDRS score.
Remission was positively correlated with age (rho = 0.426,
p = .009, df = 35), age at first disease onset (rho = 0.494, p = .002,
df = 36), and at the trend level with having bipolar disorder (rho =
0.328, p = .051, df = 34).
3.2 | PRS
Although removed from the response analysis above, the genotype
data from the dropouts were used in the PRS analysis as they still rep-
resent cases assigned to ECT.
For case–control status, a p-value threshold of 1.0 was found to
be the most informative threshold (see Figure 1a). Statistically signifi-
cantly higher PRS were found in ECT cases than controls (p = .022)
(see Figure 1b, left and right bar), explaining ΔNagelkerke R2 = 1.173%
of variance, using information from n = 83,066 SNPs.
Descriptively, PRS scores in HNR-DEP were intermediate to ECT
patients and controls (see Figure 1(b), middle bar). No statistically sig-
nificant differences were observed between ECT patients and HNR-
DEP (p = .237), or HNR-DEP and controls (p = .150).
In a partial correlation analysis we examined whether MD-PRS
differed in responders (coded 1) and nonresponders (coded 0) to
treatment. A statistically significant correlation was not observed
(rho = −0.189, p = .300, df = 30) but descriptively, the direction was
for nonresponders to have higher PRS for MD than responders. The
correlation between MD-PRS and response coded as Δ HDRS score
was also not statistically significant (rho = −0.016, p = .930, df = 31).
A statistically significant correlation was observed between MD-PRS
and alcohol dependence/abuse (rho = 0.372, p = .023, df = 35), but
no other demographic or clinical variables showed statistically signifi-
cant correlations with MD-PRS.
TABLE 1 Descriptive and clinical statistics of ECT patients
Descriptives Total (n) Mean (SD)
Age, years 45 58.38 (18.722)
Body mass index 38 25.71 (4.165)
Age at initial disease onset 38 41.29 (19.324)
Current episode length, months 37 11.38 (12.722)
Yes No
Sex (male/female) 45 22 23
Alcohol use disorder 42 6 36
Tobacco 42 12 30
Positive family history 38 19 19
Personality disorder 38 15 23
Response 37 30 7
Remission 37 14 23
HDRS baseline 42 27.26 (6.356)
HDRS final 38 10.58 (6.832)
Diagnosis 52 MDD: 32 (7 excluded),
BD: 12, SCZ: 1
Bilateral ECT 45 8 37
FIGURE 1 (a) Model fit for case–control status of MD-PRS calculated at different p-value thresholds. *p < .05, #p < .10. (b) Standardized
polygenic risk scores in: healthy controls (left, n = 172); individuals with self-reported depression, (middle, n = 376); ECT patients (right, n = 44).
Error bars denote standard error of mean
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4 | DISCUSSION
The present feasibility study represents the first usage of a whole-
genome (PRS) approach in an ECT sample. Our findings using a multi-
marker technique to characterize an important subgroup of depressed
patients show that patients assigned to ECT hold potential for further
exploration using a molecular genetics approach. These patients are
usually suffering from severe or therapy-resistant forms of depressive
episodes, which appears to be consistent with having an increased
genetic burden of disease. Individuals from the HNR cohort self-
reporting depression had scores intermediate to ECT patients and
controls, suggesting that although they indicated that they had
depression, these individuals had less genetic burden of MD.
The ability of the PRS to predict case–control status, while small
(p = .022, ΔNagelkerke R2 = 1.173%), is similar to that of other studies
using similar approaches in psychiatric genetics (on the order of 10−2
to 10−3, see also Wray et al., 2018). Although not clinically informative
at this stage, these results are consistent with depression being a
polygenic trait and suggest the potential utility of the PRS approach
to characterize patient subgroups in samples of larger size.
We did not observe statistically significant correlations between
MD-PRS and response. Descriptively, the direction was for nonre-
sponders to have higher PRS, but conclusions cannot yet be drawn as
our analysis was underpowered: because of the efficacy of ECT, the
proportion of nonresponders is necessarily small, rendering statistical
comparison a challenge, especially in a sample of the present size.
Interestingly, we observed increased MD-PRS in patients with a his-
tory of alcohol dependence/abuse, which is consistent with a large
body of research describing comorbidity between depression and
alcohol dependence at the clinical and genetic levels and supports
recent reports suggesting that genetic pleiotropy may be responsible
for this disease comorbidity (Andersen et al., 2017; Foo et al., 2018).
In a recent study, we observed that alcohol use disorder is a positive
predictor of ECT response (Aksay et al., 2017). We did not find any
such evidence in the current study, most likely because of the limited
number of nonresponders and small proportion of patients with alco-
hol dependence/abuse. Caution is needed when generalizing these
findings and confirmation in a larger sample awaits.
It is also worth mentioning that our finding that presence of
comorbid PDs was negatively correlated with the antidepressant
response to ECT corroborates previous data (de Vreede, Burger, &
van Vliet, 2005; Kaster, Goldbloom, Daskalakis, Mulsant, & Blumber-
ger, 2018; Rasmussen, 2015).
With its short time course and striking therapeutic effects, ECT
offers a good model to explore fundamental biological mechanisms
(i.e., immunological, neurotrophic, epigenetic) underlying changes in
depressive symptomatology observed as a result of treatment. Clinical
findings about the role of genetic factors suggest a possible role in
gene variation in the mediation of response to ECT (Kellner, Popeo,
Pasculli, Briggs, & Gamss, 2012); while supporting this idea, existing
data remains preliminary, highlighting the need for large-scale confir-
matory studies (Benson-Martin, Stein, Baldwin, & Domschke, 2016).
Investigations so far have only explored the candidate gene level and
to go beyond “tentative knowledge,” systematic genome-wide studies
which can identify unequivocally contributing genes are needed
(Sullivan, 2017).
Our study has several limitations. First, while ECT cohorts have
the advantage of being well-phenotyped and characterized, only
severe cases are assigned, leading to necessarily limited sample sizes.
The sample used in the current study, while large for an ECT sample,
is limited when considered in the perspective of GWAS. On the other
hand, GWAS studies often suffer from limited phenotyping at the
expense of larger numbers to gain statistical power. Further investiga-
tions which tackle both of these issues and investigate well-character-
ized, larger samples are expected to give the power needed to clarify
underlying mechanisms. For example, even samples not deeply pheno-
typed but including health record information indicating that ECT was
performed can be included.
Next, descriptively we found that population-based individuals
who had self-reported depression had lower PRS for MD than
patients assigned to ECT. It should be noted that the self-report
depression status is not equivalent to a clinical diagnosis, and this
group is potentially heterogeneous. While it has been shown that self-
reports of depression carry enough signal to be reflected in genetics
(e.g., Wray et al., 2018), comparison to a sample of expert-diagnosed
patients with MDD/BD not undergoing ECT would offer more refined
insight.
It should also be noted that our ECT cohort comprised both
patients with MDD and BD. In a post-hoc test, we examined whether
or not this affected the results of the comparison of ECT patients and
controls. After repeating the calculation with bipolar patients
excluded, we found that results did not change substantially
(R2 = 1.228%, p = .037).
Here, we have shown the potential utility of a PRS approach to
examine genetic risk for MD in patients assigned to ECT. It is impor-
tant to move in the direction of taking advantage of ECT as a model
to examine the etiology of antidepressant response as it provides a
clear pre-post treatment longitudinal design which can be investigated
using time-sensitive gene expression and epigenetic/epigenomic
methods. Further research taking advantage of such a longitudinal
design is expected to allow more in-depth exploration into both phe-
notypic changes observed and the underlying biology and eventually
will inform treatment strategies.
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